A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

By Raez Luis   Santos Edgardo   Webb R.   Wade James   Brito Roger   Karr Melissa   Kennah Andra   Childs Barrett  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1103-1110

Springer Publishing Company

Access to resources Recommend Favorite

Combination of Cisplatin and Interferon- 2a (Roferon(R)-A) in Patients with Non-small Cell Lung Cancer (NSCLC). An Open Phase II Multicentre Study

By Kataja V.   Yap A.  

European Journal of Cancer, Vol. 31, Iss. 1, 1995-01 ,pp. : 35-40

Elsevier

Access to resources Recommend Favorite

Phase II study of liarozole in advanced non-small cell lung cancer

By O'Byrne K.J.   Han C.   Mitchell K.   Lane D.   Carmichael J.   Harris A.L.   Talbot D.C.  

European Journal of Cancer, Vol. 34, Iss. 9, 1998-08 ,pp. : 1463-1466

Elsevier

Access to resources Recommend Favorite

Overexpression of periostin predicts poor prognosis in non-small cell lung cancer

By        

Oncology Letters, Vol. 6, Iss. 6, 2013-01 ,pp. : 1595-1603

Spandidos Publications

Access to resources Recommend Favorite

Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC)

By Ono Yasushi   Hino Mitsunori   Ueda Yuka   Kamizuru Ryoko   Omata Masatoshi   Uehara Takashi   Tanaka Yosuke   Soma Tomoyuki   Kudoh Shoji  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 402-406

Humana Press, Inc

Access to resources Recommend Favorite